Literature DB >> 30647827

Healthcare Costs and Absenteeism Among Caregivers of Adults with Partial-Onset Seizures: Analysis of Claims from an Employer Database.

Richard A Brook1, Krithika Rajagopalan2, James E Smeeding3.   

Abstract

BACKGROUND: Partial-onset seizures are the most common type of seizures in patients with epilepsy. In addition to the significant impact on patients, the unpredictability of seizures often also affects family members or caregivers. Caregiver burden in relation to patient treatment may help to guide treatment choices for patients. Quantitative evidence about the relationship between workplace absences, costs, and treatment burden among caregivers of patients with partial-onset seizures is lacking.
OBJECTIVE: To compare direct and indirect healthcare costs and absences among employed caregivers of patients with partial-onset seizures who are receiving monotherapy or adjunctive therapy with antiepileptic drugs (AEDs).
METHODS: This retrospective study analyzed data of employed caregiver spouses of patients with partial-onset seizures and paired them with the patients into 2 groups based on the patient's therapy: the monotherapy cohort or the adjunctive therapy cohort (ie, >90 days of concomitant use of ≥2 AEDs). Patients and caregivers had to have ≥12 months of continuous data after the index date. Separate 2-part regression models were used to compare direct medical and prescription costs; indirect costs (ie, sick leave, short-term and long-term disability, and workers' compensation); and differences in work absences for caregivers.
RESULTS: The baseline caregivers' characteristics were similar in the monotherapy cohort (N = 238) and the adjunctive therapy cohort (N = 129). Caregivers' total direct costs were $4231 in the monotherapy cohort and $7217 in the adjunctive therapy cohort. The caregivers of patients in the monotherapy cohort were less likely to use inpatient hospital services than caregivers of patients in the adjunctive therapy cohort (1.3% vs 9.9%, respectively; P = .0016). The caregivers' total indirect costs were $912 and $1192 in the monotherapy and adjunctive therapy cohorts, respectively. Sick days were significantly lower in the monotherapy cohort (2.4 days vs 4.4 days annually; P <.0001), with an associated cost difference of $541.
CONCLUSION: Caregivers of patients with partial-onset seizures in the adjunctive therapy cohort had significantly greater medical and sick day costs than caregivers in the monotherapy cohort. These findings suggest that higher treatment burden among patients with epilepsy is associated with greater direct and indirect healthcare costs for their caregivers.

Entities:  

Keywords:  absenteeism; adjunctive therapy; antiepileptic drugs; caregiver burden; caregivers; direct healthcare cost; epilepsy; indirect healthcare cost; monotherapy; partial-onset seizures; treatment decision-making

Year:  2018        PMID: 30647827      PMCID: PMC6306097     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN: 1942-2962


  20 in total

1.  Costs, work absence, and adherence in patients with partial onset seizures prescribed gabapentin or pregabalin.

Authors:  Nathan L Kleinman; Alesia Sadosky; Jaren Seid; Roy C Martin; David M Labiner
Journal:  Epilepsy Res       Date:  2012-05-14       Impact factor: 3.045

2.  An employer perspective on annual employee and dependent costs for pediatric asthma.

Authors:  Nathan L Kleinman; Richard A Brook; Sulabha Ramachandran
Journal:  Ann Allergy Asthma Immunol       Date:  2009-08       Impact factor: 6.347

3.  A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures.

Authors:  A P Aldenkamp; G Baker; O G Mulder; D Chadwick; P Cooper; J Doelman; R Duncan; C Gassmann-Mayer; G J de Haan; C Hughson; J Hulsman; J Overweg; G Pledger; T W Rentmeester; H Riaz; S Wroe
Journal:  Epilepsia       Date:  2000-09       Impact factor: 5.864

4.  Social support for self-management behaviors among people with epilepsy: a content analysis of the WebEase program.

Authors:  Elizabeth Reisinger Walker; Yvan Bamps; Andrea Burdett; Jennifer Rothkopf; Colleen Diiorio
Journal:  Epilepsy Behav       Date:  2012-02-23       Impact factor: 2.937

Review 5.  Epilepsy and the family: a review of current literature.

Authors:  N Ellis; D Upton; P Thompson
Journal:  Seizure       Date:  2000-01       Impact factor: 3.184

6.  Examining the relationships of depressive symptoms, stigma, social support and regimen-specific support on quality of life in adult patients with epilepsy.

Authors:  A D Whatley; C K DiIorio; K Yeager
Journal:  Health Educ Res       Date:  2010-02-18

Review 7.  The global burden and stigma of epilepsy.

Authors:  Hanneke M de Boer; Marco Mula; Josemir W Sander
Journal:  Epilepsy Behav       Date:  2008-02-14       Impact factor: 2.937

8.  Psychosocial factors associated with stigma in adults with epilepsy.

Authors:  Gigi Smith; Pamela L Ferguson; Lee L Saunders; Janelle L Wagner; Braxton B Wannamaker; Anbesaw W Selassie
Journal:  Epilepsy Behav       Date:  2009-09-24       Impact factor: 2.937

9.  Quality of life and burden in caregivers of patients with epilepsy.

Authors:  Ana Carolina Westphal-Guitti; Neide Barreira Alonso; Rosa Cristina Vaz Pedroso Migliorini; Tatiana Indelicato da Silva; Auro Mauro Azevedo; Luís Otávio Sales Ferreira Caboclo; Américo Ceiki Sakamoto; Elza Márcia Targas Yacubian
Journal:  J Neurosci Nurs       Date:  2007-12       Impact factor: 1.230

10.  Comorbidity in adults with epilepsy--United States, 2010.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-11-01       Impact factor: 17.586

View more
  1 in total

Review 1.  The burden of epilepsy and unmet need in people with focal seizures.

Authors:  Persefoni Ioannou; Daniella L Foster; Josemir W Sander; Sophie Dupont; Antonio Gil-Nagel; Ewa Drogon O'Flaherty; Elena Alvarez-Baron; Jasmina Medjedovic
Journal:  Brain Behav       Date:  2022-08-26       Impact factor: 3.405

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.